© 1996 British Society for Rheumatology
other |
TRABECULAR AND CORTICAL BONE LOSS IN SYSTEMIC LUPUS ERYTHEMATOSUS
*General Internal Medicine, St-Luc University Hospital, Louvain University in Brussels Belgium
Departments of Rheumatology, St-Luc University Hospital, Louvain University in Brussels Belgium
Correspondence to:
Correspondence to: F. A. Houssiau, Rheumatology Department, UCL 5390, Avenue Hippocrate 10, B-1200 Brussels, Belgium.
We measured lumbar spine, hip (total and sub-regions) and total body bone mineral densities (BMDs) by dual-energy X-ray absorptiometry (DXA) in 47 premenopausal female patients suffering from systemic lupus erythematosus (SLE). As compared to healthy controls, SLE patients had lower BMDs at all trabecular and cortical sites. Comparison of BMDs between patients ever and never treated with glucocorticoids indicated that patients who had ever received glucocorticoids had a significantly lower lumbar spine BMD compared to those who never did. Moreover, bone loss in patients ever treated with glucocorticoids was commensurate with their cumulated oral glucocorticoid intake. Interestingly, patients never treated with glucocorticoids had a lower hip BMD compared to controls, thereby suggesting that the disease per se might induce some bone loss. Taken together, SLE patients suffer from a significant trabecular and cortical bone loss indicative of an increased risk of future fracture.
KEY WORDS: Systemic lupus erythematosus, Bone, Densitometry, Glucocorticoids
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Lilleby Review: Bone status in juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 580 - 586. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Lee, O. Almagor, D. D. Dunlop, S. Manzi, S. Spies, A. B. Chadha, and R. Ramsey-Goldman Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids Rheumatology, January 1, 2006; 45(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A N. Toukap, G Depresseux, J-P Devogelaer, and F A Houssiau Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients Lupus, July 1, 2005; 14(7): 517 - 520. [Abstract] [PDF]
|
|
|
|
 |
|
 F. A. Houssiau Management of Lupus Nephritis: An Update J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704. [Full Text] [PDF]
|
|
|
|
|
|
C A Pineau, M B Urowitz, P J Fortin, D Ibanez, and D D Gladman Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density Lupus, June 1, 2004; 13(6): 436 - 441. [Abstract] [PDF]
|
|
|
|
|
|
Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{ Lupus, June 1, 2002; 11(6): 356 - 361. [Abstract] [PDF]
|
|
|
|
|
|
D. Jardinet, C. Lefebvre, G. Depresseux, M. Lambert, J.-P. Devogelaer, and F. A. Houssiau Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine Rheumatology, April 1, 2000; 39(4): 389 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O. Abu, A. Horner, V. Kusec, J. T. Triffitt, and J. E. Compston The Localization of the Functional Glucocorticoid Receptor {alpha} in Human Bone J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 883 - 889. [Abstract] [Full Text]
|
|
|
|
 |
|
 I.-M. Gilboe, T. K Kvien, G. Haugeberg, and G. Husby Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls Ann Rheum Dis, February 1, 2000; 59(2): 110 - 115. [Abstract] [Full Text]
|
|